Upadacitinib: A Convenient and Effective Alternative Treatment for Spondyloarthritis

By Staff Writer

February 3, 2023

Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and/or Visual Analogue Scale (VAS) score to measure this. A cost comparison shows that upadacitinib costs about the same and provides similar health benefits as secukinumab and ixekizumab.

The update suggests considering upadacitinib as an alternative to the National Institute for Health and Care Excellence (NICE) recommended Interleukin (IL)-17 inhibitors. This is especially important if conventional therapy doesn’t control the condition well enough or if TNF-alpha inhibitors aren’t suitable or effective.

Clinical and patient experts highlighted the convenience of upadacitinib over IL-17 inhibitors owing to its oral administration.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.